CALL US
+44 (0)1462 440 084
|
+1 919-882-2016
Contact
Submit RFI
Home
Who are we?
Approach
News
Services
Biostatistics
Biostatistical Consulting
Statistical Programming
Clinical Data Management
Medical Writing
Regulatory Submission Review
Pharmacovigilance
Expertise
Clinical Trial Phases
ISS ISE Services
Therapeutic Experience
PK Analysis
CDISC Compliant/Mapping
Bayesian Adaptive Designs
Functional Service Provider
Technology
Data Quality Oversight
Remote Monitoring
Clinical Data Visualizations
Pharmacovigilance Safety Database
IQ - Integrated Quanticate®
Resources
Whitepapers
Events
Case Studies
Hemophilia Case Study
FSP Model Case Study
Biostatistics & Programming FSP Case Study
Clinical Data Management Case Study
Biosimilar Development Case Study
ISS ISE Case Study
Centralized Statistical Monitoring
Clinical Outsourcing Trends
What is a data-focused CRO?
Careers
Graduate Jobs
UK
India
North America
South Africa
Poland
Vacancies
Blog
COVID-19
Statistics Rescue Package
COVID-19 Clinical Trial Support
COVID-19 Webinar: Ensuring Scientific Integrity
Preserving Integrity of Trials During COVID-19
COVID-19 Resources
[Free White Paper]
Bayesian Study Design
Using Interim Analyses to Improve Efficiency in Drug Development
This second whitepaper
shows how the Bayesian framework is highly appropriate for planning and executing interim
analyses
:
The rationale for using a Bayesian approach to interim analyses is explained.
The formulation of interim decision rules on the basis of posterior and predictive probability is introduced and evaluated using a case study.
The value of simulations are included to assess the merits of the different decision rules and the relative timing of interim analyses is illustrated.
To receive a copy, please fill out the form.
Download this paper